Daily Health Headlines

New Version of RA Drug Enbrel: FAQ

👤by WebMD 0 comments 🕔Friday, September 2nd, 2016

By Jennifer Clopton

Reviewed by Michael W. Smith, MD

Sept. 1, 2016 -- The FDA cleared the way for what is hoped may be a more affordable version of the popular arthritis drug Enbrel. Tuesday the agency approved Erelzi (etanercept-szzs), a "biosimilar" to Enbrel.

The FDA says the two medications work the same way and are both safe and effective. The industry stops short of calling this a generic version of Enbrel, however, because the two drugs have minor differences that keep them from being considered exactly the same.

Enbrel is one of the most widely used biologics on the market. It was approved in 1998 to treat moderate to severe rheumatoid arthritis (RA) and earned more than $5 billion in sales last year. But the high price tag of Enbrel and other biologics make them too expensive for many people -- sometimes $3,000 or more a month.

But patients may have to wait for those cost savings from Erelzi a bit longer. Legal wrangling could delay its release, so it's unclear when it may be available.

Here is some more information about Erelzi:

What is the new drug used to treat?

Erelzi is given by injection. It can be used to treat the same diseases as Enbrel. That includes:

Moderate to severe RA, either on its own or in combination with the drug methotrexate Moderate to severe juvenile arthritis in patients over the age of 2 Psoriatic arthritis in combination with methotrexate in patients who don't respond to that drug by itself Active ankylosing spondylitis Moderate to severe plaque psoriasis in patients over the age of 18 How does it work?

With diseases like RA, your body makes too much of a protein called tumor necrosis factor, or TNF. That causes inflammation, joint swelling, and pain.

Erelzi and Enbrel block the effects of the protein, lowering inflammation and pain. That can stop joint damage and in some cases even reverse it.

What is a biosimilar drug?

Biologic drugs are made from parts of living organisms. They have transformed the treatment of inflammatory diseases and offer an alternative to people who don't respond well to traditional drugs.

The Affordable Care Act allowed for the creation of biosimilars, which are near copies of biologics. The FDA says they have only "minor" differences.

Erelzi is the third biosimilar approved by the FDA. A biosimilar to Humira, which treats many of the same types of inflammatory diseases, received approval from an FDA panel in July. The agency is expected to announce a decision on final approval this month.

How well does Erelzi work?

The FDA reviewed four studies in 216 healthy people comparing Enbrel and Erelzi and a study in 531 people with chronic plaque psoriasis who randomly received one of the two drugs. Those studies showed no differences in the two groups, researchers say.

"A biosimilar is almost identical in structure to the parent drug and there should not be any problem taking it, although long-term safety data is lacking," says Yousaf Ali MD, chief of rheumatology at The Mount Sinai Hospital in New York.

Who shouldn't take it?

People with sepsis (a blood infection) or who have an active infection should not take Erelzi, according to the FDA and the manufacturer, Sandoz Inc. Children should get their vaccines before starting Erelzi, according to Sandoz, as live vaccines taken with the medication could weaken a child's immune system. The same cautions are in place for Enbrel.

What are the side effects?

Common side effects include infections and injection site reactions, according to the FDA. Other side effects include headaches and upper respiratory or sinus infections, according to Sandoz.

More serious side effects, however, have been reported. Those are rare and include tuberculosis and other invasive fungal infections, which can be fatal, according to Sandoz. In addition, lymphoma and other cancers, some fatal, have been reported in children and teens. The side effects are the same seen with Enbrel.

Erelzi will contain a "black box warning" on the increased risk of serious infections like tuberculosis and fungal infections, the FDA says. It also notes that lymphoma and other cancers have been reported.

When will it be available, what will it cost, and will insurance cover it?

In theory, biosimilars should be cheaper than the biologics they are based on. But a spokesperson for Sandoz says Erelzi doesn't have a price yet.

Duncan Cantor, global head of external relations for Sandoz, says it will be "competitively priced." For comparison, a month's supply of Enbrel is about $4,000.

Ali says insurance coverage will affect how often doctors prescribe the drug. He says he would only switch from Enbrel if the cost of that drug was prohibitive. "It would be inappropriate to switch patients who are stable on Enbrel to Erelzi purely due to cost saving since there would be a theoretical risk of disease worsening or lack of response," he says.

There's no release date yet for Erelzi. Amgen Inc., the maker of Enbrel, filed lawsuit against Sandoz to stop it from selling Erelzi, says Amgen spokesperson Kristen Davis. The company says the drug violates its patent for Enbrel.

A court trial is scheduled for April 2018.

Article Credits / Source


WebMD provides up to the minute breaking health news. Click here to view this full article from WebMD.

SOURCES: Yousaf Ali MD, chief of rheumatology, The Mount Sinai Hospital in New York. Duncan Cantor, Sandoz global head of external relations. Kristen Davis, Amgen spokesperson. Enbrel.com: "What is Enbrel," "How Enbrel works." Novartis: "FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases." FDA: "What Are "Biologics" Questions and Answers," "Information on Biosimilars," "FDA approves Erelzi, a biosimilar to Enbrel." FDA, Sandoz Briefing Information for July 13, 2016 Meeting of the Arthritis Advisory Committee.

View More Articles From WebMD 🌎View Article Website

Sponsored Product

Lunar Sleep for $1.95

Lunar Sleep for $1.95

People who have trouble sleeping typically have low levels of melatonin, so melatonin supplements seem like a logical fix for insomnia. There is a high demand for sleep aids, especially in the U.S. The National Health Interview Survey done in 2002, and again in 2007, found 1.6 million US adults were using complementary and alternative sleep aids for insomnia. Lunar Sleep was a top choice. Use Promo Code: Sleep2014 and only pay $1.95 S&H.

Get Lunar Sleep for $1.95

More Arthritis Articles

Delays in Lupus Care Seen Among Minorities, Less Educated

Delays in Lupus Care Seen Among Minorities, Less Educated0

FRIDAY, Nov. 18, 2016 (HealthDay News) -- Delays in lupus treatment are more common among Americans who are black, Asian or are less educated, a new study finds. Lupus is a chronic autoimmune disease in which inflammation affects the skin, ...

Having Rheumatoid Arthritis May Increase Heart Risk

Having Rheumatoid Arthritis May Increase Heart Risk0

TUESDAY, Nov. 15, 2016 (HealthDay News) -- People with rheumatoid arthritis may have an increased risk for a heart attack, stroke and other heart disease-related problems, a new study suggests. Researchers examined data from 353 rheumatoid ...

Rheumatoid Factor (RF)

Rheumatoid Factor (RF)0

What Is Rheumatoid Arthritis (RA)? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly attacked by their own ...

Health Tip: Keep Psoriatic Arthritis Fatigue in Check

Health Tip: Keep Psoriatic Arthritis Fatigue in Check0

(HealthDay News) -- Fatigue is a common problem for people with psoriatic arthritis. According to the National Psoriasis Foundation, some studies indicate that half of all psoriatic arthritis patients have moderate-to-severe fatigue. The ...

Osteoarthritis Symptoms

Osteoarthritis Symptoms0

Comment by William C. Shiel Jr., MD, FACP, FACR Common osteoarthritis symptoms and signs Symptoms of osteoarthritis vary greatly from patient to patient and they depend on the severity of cartilage loss and the joint(s) affected. Many people ...

View More Arthritis Articles


Write a Comment

Your email address will not be published. Required fields are marked *

Our Mailing List

Subscribe to our mailing list to get the latest health news as it breaks!

Your information will not be shared with anyone!